(Circulation. 1995;91:1341-1346.)
© 1995 American Heart Association, Inc.
Articles |
Circadian Variation in the Efficacy of Tissue-Type Plasminogen Activator
Presented in part at the American Heart Association Scientific Sessions, Anaheim, Calif, November 12, 1991.
From the Department of Medicine, Cooper Hospital/University Medical Center, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Camden, NJ.
Background The frequency of onset of acute myocardial infarction follows a circadian pattern, with a peak incidence between 6:00 AM and noon. Circadian variations have been defined for platelet aggregation, plasminogen-activator inhibitor, and a number of hemostatic and physiological factors, all of which might predispose toward clotting in the late morning and thrombolysis in the evening. Thus, the hypothesis for this retrospective analysis was that tissue-type plasminogen activator (TPA) has greater efficacy when administered between noon and midnight, as measured by coronary patency 90 minutes after initiation of treatment.
Methods and Results Seven hundred twenty-eight patients were enrolled in either of two studies in which TPA was administered under a uniform protocol for the treatment of acute myocardial infarction. Of these, 692 patients had qualifying arteriograms that allowed standardized assessment by a core angiographic laboratory of the primary end point of 90-minute patency. TPA has a circadian pattern of efficacy, with greater TIMI grade 3 patency when administered between noon and midnight (P<.001). When TPA was given within 2 hours of symptoms (n=127), the total patency was highest and there was a trend (P=.055) toward the greatest magnitude difference occurring between AM and PM patency. The onset of myocardial infarction was confirmed to have a marked circadian variation with a peak incidence about 10:00 AM. The peak efficacy of TPA was about 8:00 PM, representing a phase difference of about 10 hours after peak infarction incidence.
Conclusions There is a circadian variation in the ability of TPA to rapidly open coronary arteries, with highest efficacy between noon and midnight. This complements clinical and in vitro knowledge of increased morning thrombosis and is concordant with knowledge of a fibrinolytic profile that is more favorable for evening lysis. This finding has implications for understanding the circadian pathophysiology of myocardial infarction and for its chronotherapy.
Key Words: circadian rhythm • plasminogen activators • thrombolysis • myocardial infarction
This article has been cited by other articles:
 |
|
 |
|
  D. F. Reilly, E. J. Westgate, and G. A. FitzGerald Peripheral Circadian Clocks in the Vasculature Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1694 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Ornato, J. E. Muller, E. S. Froelicher, and R. A. Kloner Task Force II: Indirect and Secondary Cardiovascular Effects of Biological Terrorism Agents and Diseases J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1389 - 1397. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Manfredini, B. Boari, R. Salmi, A. M. Malagoni, and F. Manfredini Circadian Rhythms and Reperfusion in Patients With Acute ST-Segment Elevation Myocardial Infarction JAMA, December 14, 2005; 294(22): 2846 - 2847. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Manfredini, B. Boari, P. G. Steg, E. Bonnefoy, P. Touboul, S. Chabaud, A. Leizorovicz, F. Lapostolle, P.-Y. Dubien, and P. Cristofini Impact of Time to Treatment on Mortality After Prehospital Fibrinolysis or Primary Angioplasty * Response Circulation, May 11, 2004; 109(18): e219 - e219. [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Reisin, N. Pancheva, M. Berman, V. Khalameizer, J. Jafary, C. Yosefy, Y. Blaer, I. Manevich, R. Peled, and S. Scharf Circadian Variation of the Efficacy of Thrombolytic Therapy in Acute Myocardial Infarction--Isn't the Time Ripe for Cardiovascular Chronotherapy? Angiology, May 1, 2004; 55(3): 257 - 263. [Abstract] [PDF]
|
|
|
|
|
|
J. P. S. Henriques, A. P. Haasdijk, F. Zijlstra, and Zwolle Myocardial Infarction Study Group Outcome of primary angioplasty for acute myocardial infarction during routine duty hours versus during off-hours J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2138 - 2142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Schoenhard, M. Eren, C. H. Johnson, and D. E. Vaughan Alternative splicing yields novel BMAL2 variants: tissue distribution and functional characterization Am J Physiol Cell Physiol, July 1, 2002; 283(1): C103 - C114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Englund, S. Behrens, K. Wegscheider, E. Rowland, and for the European 7219 Jewel Investigators Circadian variation of malignant ventricular arrhythmias in patients with ischemic and nonischemic heart disease after cardioverter defibrillator implantation J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1560 - 1568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Goldhammer, L Kharash, and E G Abinader Circadian fluctuations in the efficacy of thrombolysis with streptokinase Postgrad. Med. J., November 1, 1999; 75(889): 667 - 671. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. J. Brown, M. A. Agirbasli, G. H. Williams, W. R. Litchfield, and D. E. Vaughan Effect of Activation and Inhibition of the Renin-Angiotensin System on Plasma PAI-1 Hypertension, December 1, 1998; 32(6): 965 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Krantz, W. J. Kop, F. H. Gabbay, A. Rozanski, M. Barnard, J. Klein, Y. Pardo, and J. S. Gottdiener Circadian Variation of Ambulatory Myocardial Ischemia : Triggering by Daily Activities and Evidence for an Endogenous Circadian Component Circulation, April 1, 1996; 93(7): 1364 - 1371. [Abstract] [Full Text]
|
|
|
|
|
|
E. Braunwald Morning Resistance to Thrombolytic Therapy Circulation, March 1, 1995; 91(5): 1604 - 1606. [Full Text]
|
|